101. All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia
- Author
-
Reza Mirfakhraie, Bentolhoda Kuhestani Dehaghi, Mahmoud Dehghani Ghorbi, Haniyeh Ghaffari-Nazari, Mozhdeh Mohammadian, Maryam Salimi, Maria Tavakoli Ardakani, and Sayeh Parkhideh
- Subjects
Acute lymphoblastic leukemia ,Lymphoma ,Blinatumomab ,Minimal residual disease ,Relapsed/refractory ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Introduction: B cell acute lymphoblastic leukemia-lymphoma (B-ALL) accounts for approximately 75% of ALL cases and is observed in children and adults. Recent advances in disease diagnosis, stratification and prognostication have led to a better characterization of different subgroups of ALL. Notwithstanding the significant improvement in the complete remission rate of B-ALL, patients with minimal residual disease (MRD) and relapsed/refractory (R/R) settings suffer from poor outcomes. Hypothesis: However, novel therapies, such as agents targeting tyrosine kinases or the CD20 molecule, combination therapies and improved supportive care, have changed the treatment landscape of B-ALL. Method and results: Meanwhile, blinatumomab has been FDA-approved for MRD-positive or R/R B-ALL patients. Blinatumomab is a bispecific T cell engager containing the CD3 and CD19 that recognize domains redirecting cytotoxic T cells to lyse B cells. Promising outcomes, including long-term overall survival and improved MRD-negative response rates, have been reported in patients who received this drug. Adding blinatumomab to new ALL regimens seems promising for achieving better outcomes in poor prognosis B-ALL patients. Nevertheless, the neurotoxicity and cytokine release syndrome are the two major adverse events following the blinatumomab therapy. Conclusion: This review summarizes the function and effectiveness of blinatumomab in R/R and MRD positive B-ALL patients. Furthermore, blinatumomab's positive and negative aspects as a novel therapy for B-ALL patients have been briefly discussed.
- Published
- 2024
- Full Text
- View/download PDF